Literature DB >> 7296486

Advanced ovarian carcinoma: response to antiestrogen therapy.

A M Myers, G E Moore, F J Major.   

Abstract

Three patients with Stage III serous cystadenocarcinoma of the ovary were successfully treated with estrogen antagonist therapy after failure of cytotoxic chemotherapy. All had histologic confirmation of progressive or persistent disease. High titers of estrogen receptor protein (ERP) and progesterone receptor protein (PRP) were detected in one patient prior to tamoxifen therapy. One patient had a complete remission lasting for 18 months. The other patients had partial responses and were able to return to normal activities. Simultaneous or prior sequential cytotoxic chemotherapy did not negate the effectiveness of the estrogen antagonists.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7296486     DOI: 10.1002/1097-0142(19811201)48:11<2368::aid-cncr2820481105>3.0.co;2-j

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  6 in total

Review 1.  Developing new drugs for ovarian cancer: a challenging task in a changing reality.

Authors:  R M Canetta; S K Carter
Journal:  J Cancer Res Clin Oncol       Date:  1984       Impact factor: 4.553

2.  Hormonal aspects of ovarian malignancy.

Authors:  J Waxman
Journal:  J R Soc Med       Date:  1984-03       Impact factor: 5.344

3.  An Effective Hormonal Therapy for a Patient with Estrogen Receptor 1 (ESR1)-Amplified Metastatic Ovarian Cancer: A Case Report.

Authors:  Yue Wang; Shuang Tan; Evenki Pan; Yutong Ma; Xue Wu; Zhe Yu; Kui Jiang
Journal:  Onco Targets Ther       Date:  2022-06-09       Impact factor: 4.345

4.  Cloning ovarian carcinoma cells in an agar double layer versus a methylcellulose monolayer system. A comparison of two methods.

Authors:  H M Runge; H A Neumann; W Bücke; A Pfleiderer
Journal:  J Cancer Res Clin Oncol       Date:  1985       Impact factor: 4.553

5.  In vitro responsiveness of ovarian epithelial carcinomas to endocrine therapy.

Authors:  H M Runge; G Teufel; J Neulen; H Geyer; A Pfleiderer
Journal:  Cancer Chemother Pharmacol       Date:  1986       Impact factor: 3.333

6.  Tamoxifen in refractory ovarian cancer: the use of a loading dose schedule.

Authors:  R J Osborne; S T Malik; M L Slevin; V J Harvey; J Spona; H Salzer; C J Williams
Journal:  Br J Cancer       Date:  1988-01       Impact factor: 7.640

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.